X-Received: by 2002:a05:600c:1553:b0:39c:87fc:579e with SMTP id f19-20020a05600c155300b0039c87fc579emr2166250wmg.102.1656127497378;
Fri, 24 Jun 2022 20:24:57 -0700 (PDT)
X-Received: by 2002:a81:a208:0:b0:314:7e4d:30e1 with SMTP id
w8-20020a81a208000000b003147e4d30e1mr2432898ywg.415.1656127496678; Fri, 24
Jun 2022 20:24:56 -0700 (PDT)
Path: i2pn2.org!i2pn.org!usenet.blueworldhosting.com!feed1.usenet.blueworldhosting.com!peer01.iad!feed-me.highwinds-media.com!news.highwinds-media.com!news-out.google.com!nntp.google.com!postnews.google.com!google-groups.googlegroups.com!not-for-mail
Newsgroups: uk.comp.homebuilt
Date: Fri, 24 Jun 2022 20:24:56 -0700 (PDT)
Injection-Info: google-groups.googlegroups.com; posting-host=45.87.214.77; posting-account=9Kbi_QoAAABE1YQjgR7wlUg-gmInqQ-9
NNTP-Posting-Host: 45.87.214.77
User-Agent: G2/1.0
MIME-Version: 1.0
Message-ID: <acd1aeec-78e1-4fb3-a3d5-9533a50cef38n@googlegroups.com>
Subject: (PDF) Development of Antibody-Based Therapeutics 2nd Edition by Tabrizi
From: hesterho...@gmail.com (hester holt)
Injection-Date: Sat, 25 Jun 2022 03:24:57 +0000
Content-Type: text/plain; charset="UTF-8"
X-Received-Bytes: 1257